Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy

Zhiyan Li1, Xianghui Li1, Shichao Ai1

  • 1Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People's Republic of China.

Insights

Starvation therapy uses nanomaterials to target cancer's glucose metabolism, overcoming limitations of traditional methods. This approach shows promise for inhibiting tumor growth and improving cancer treatment efficacy.

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Metabolic Pathways

Background:

  • Cancer cells exhibit increased nutrient uptake and altered metabolic pathways, particularly glucose metabolism.
  • Starvation therapy targets cancer's reliance on glucose, aiming to disrupt tumor growth.
  • Existing starvation therapies face challenges in targeting effectiveness and drug tolerance.

Purpose of the Study:

  • To review recent advancements in nanomaterial-assisted starvation therapy for cancer.
  • To discuss the design and mechanisms of nanosystems used in starvation therapy.
  • To highlight obstacles and future potential for these anticancer strategies.

Main Methods:

  • Review of representative research on nanosystems for starvation therapy.
  • Analysis of traditional glucose oxidase-based treatments.
  • Examination of novel small molecule agents targeting glucose metabolism.

Main Results:

  • Nanomaterial-assisted starvation therapy shows significant progress as monotherapy or combination treatment.
  • Nanosystems offer improved targeting effectiveness and overcome drug tolerance issues.
  • Diverse strategies, including glucose oxidase and small molecule agents, are being developed.

Conclusions:

  • Nanomaterial-assisted starvation therapy represents a promising strategy for cancer treatment.
  • Further research is needed to address obstacles and advance clinical translation.
  • The integration of nanotechnology offers new avenues for targeting cancer metabolism.

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
254
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
332
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
284
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.2K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.5K